About 347 million people worldwide have diabetes.1 In many cases this leads to perihperal artery disease.
"The high prevalance of chronic renal impairment in diabetic patients with PAD and the need for high doses of gadolinium based contrast agents place them at risk for nephrogenic system fibrosis."2
QISS3 provides an accurate non-contrast alternativeto CE-MRA for demonstrating clinically significant arterial disease in patients where contrast agents are contraindicated.2,4 Enhance clinical capabilities with access to latest clinical standards of care and improve patient safety with the reduced need for CE-MRA.
"QISS MRA should become the non-contrast MRA technique of choice in patients with renal dysfunction."5
Maria Carr, Research Technologist Northwestern University Feinberg School of Medicine Chicago, US
The statements by Siemens' customers described herein are based on results that were achieved in the customer's unique setting. Since there is no "typical" hospital and many variables exist (e.g., hospital size, case mix, level of IT adoption) there can be no guarantee that other customers will achieve the same results.